Efficacy and Safety Study of Meditoxin® to Treat Essential Blepharospasm

Multi-center, Phase Ⅳ, Single Arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Meditoxin® in Subjects With Essential Blepharospasm

The purpose of this study is to evaluate the efficacy and safety of Meditoxin® in the treatment of Essential blepharospasm.

Inclusion Criteria:

• Men and women aged above 18
• Subjects who was diagnosed with Essential Blepharospasm
• Subjects who voluntarily Signed written informed consent
• Subjects who can adhere to protocol and study requirements

Exclusion Criteria:

• Subjects with known history of allergy considered due to Botulinum toxin type A
• Subjects who have received botulinum toxin A type within 3 months
• Any disease that might affect neuromuscular function (e.g.. Myasthenia Gravis, Lambert-Eaton Syndrome, Amyotrophic Lateral Sclerosis ect.)
• Subjects who are participating in other clinical trials
• Pregnant or lactating female Subjects
• Subjects who are not eligible for the study at the discretion of the Investigator.